Galapagos Q4 Earnings Call Highlights

Core Insights - Galapagos is undergoing a strategic reset, focusing on business development in inflammation & immunology and oncology, while winding down its cell therapy activities [4][7][17] Financial Performance - The company reported an operating profit of €295.1 million for 2025, primarily due to the recognition of €1.069 billion in deferred income from Gilead [5][8] - Galapagos ended 2025 with approximately €2.998 billion in cash, down from €3.317 billion at the end of 2024, with a significant portion held in U.S. dollars [11][12] Research and Development - The TYK2 inhibitor GLPG3667 achieved positive Phase 2 results in dermatomyositis and systemic lupus erythematosus, but the company lacks the infrastructure for Phase 3 trials and is seeking partners for further development [6][7] Strategic Direction - The company is prioritizing "clinically de-risked opportunities" and leveraging its collaboration with Gilead as a strategic advantage [2][4] - A new leadership team has been assembled, and the board has been refreshed with directors experienced in capital allocation and operations [3][4] Future Guidance - For 2026, the company expects to be cash flow neutral to positive by year-end, with a projected cash outflow of up to €50 million in Q1 related to the wind-down of cell therapy [13][15] - The wind-down of cell therapy activities is expected to be substantially completed by the end of Q3 2026 [13][16]